Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HS-20094 in Overweight and Obese Subjects
NCT06118021Phase 2Completed
- Sponsor
- Hansoh Pharmaceutical Group
- Start
- Oct 2023
- Primary completion
- Aug 2024
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of olatorepatide in obesity (4 arms), sponsored by Hansoh Pharmaceutical Group. Primary endpoint: Percent Change from Baseline in Body Weight at 24 weeks. Started Oct 2023; status: completed.
02
Drugs
olatorepatide
03
Conditions
obesity
Beyond the preview
Go deeper on NCT06118021.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06118021.